When the enrolled population in a study doesn’t reflect how patients are actually treated, clinical trial demographics that look statistically sound on paper can lead to challenges with labeling,...
Read More
One of the most overlooked challenges in clinical research is the travel distance required of participants. According to the American Society of Clinical Oncology (ASCO), over half of oncology trial...
Read More
Why Retention Matters More Than Ever GLP-1 programs often include extended ocular safety follow-up (e.g., 24–36 months). Sustained retention preserves statistical power and reduces bias; across...
Read More
How sponsors keep patient enrollment moving and avoid ocular assessment bottlenecks When recruitment outpaces assessment capacity, timelines slip, and qualified participants disengage. Traditional,...
Read More
In today’s funding environment, sponsors cannot afford preventable rework on ocular endpoints. Regulators are closely examining a potential link between GLP-1 receptor agonists and non-arteritic...
Read More
In today’s capital-constrained clinical landscape, every protocol deviation, rescreen, and unplanned patient visit translates into real financial and timeline risk. Ocular endpoints, such as BCVA,...
Read More
Legacy ophthalmic trial sites were built using traditional models. These solutions have done an admirable job and have advanced research exponentially, but as the industry continues to evolve,...
Read More
GLP-1 receptor agonists, such as semaglutide, have emerged as powerful therapeutic agents, transforming the management of type 2 diabetes, weight management, and cardiovascular health.
Read More